Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1983 Sep;16(3):313–318. doi: 10.1111/j.1365-2125.1983.tb02167.x

The effective plasma concentrations of sulmazol (AR-L 115 BS) on haemodynamics in chronic heart failure.

M Renard, P Jacobs, P Mols, C Melot, A Dresse, R Bernard
PMCID: PMC1428014  PMID: 6626424

Abstract

Sulmazol (AR-L 115 BS) is a new inotropic drug which has arterial and venous vasodilating properties. We used it in seven patients with severe refractory heart failure to determine the effective plasma concentration levels and the most effective bolus dose on haemodynamics. The haemodynamic monitoring included a Swan-Ganz catheter in the pulmonary artery and a radial catheter. Haemodynamic measurements and plasma concentration determinations were performed before sulmazol injection and at 5, 10 and 30 min after a bolus 0.25, 0.50, 0.75 mg/kg. We observed a gradual increase in cardiac index and decrease in pulmonary wedge pressure when plasma concentration levels rose but the beneficial effects were mainly observed for sulmazol plasma concentrations above 1 microgram/ml. A bolus injection of 0.75 mg/kg was effective in all cases: a significant increase of cardiac index (1.9 to 2.5 1 min-1 m-2; P less than 0.001) and a significant decrease in pulmonary wedge pressure (30 to 25 mm Hg; P less than 0.005) and right atrial pressure (13 to 10 mm Hg, P less than 0.01) were observed. In these patients sulmazol improved the severely deteriorated left ventricular function without affecting heart rate and blood pressure.

Full text

PDF
313

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Awan N. A., Evenson M. K., Needham K. E., Evans T. O., Hermanovich J., Taylor C. R., Amsterdam E., Mason D. T. Hemodynamic effects of oral pirbuterol in chronic severe congestive heart failure. Circulation. 1981 Jan;63(1):96–101. doi: 10.1161/01.cir.63.1.96. [DOI] [PubMed] [Google Scholar]
  2. Bourdillon P. D., Dawson J. R., Foale R. A., Timmis A. D., Poole-Wilson P. A., Sutton G. C. Salbutamol in treatment of heart failure. Br Heart J. 1980 Feb;43(2):206–210. doi: 10.1136/hrt.43.2.206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brutsaert D. L., De Clerck N. M., Housmans P. R., Van Ocken E. R. Effects of AR-L 115 on contraction and relaxation of isolated mammalian cardiac muscle. J Cardiovasc Pharmacol. 1982 May-Jun;4(3):333–343. doi: 10.1097/00005344-198205000-00001. [DOI] [PubMed] [Google Scholar]
  4. Desch C. E., Magorien R. D., Triffon D. W., Blanford M. F., Unverferth D. V., Leier C. V. Development of pharmacodynamic tolerance to prozosin in congestive heart failure. Am J Cardiol. 1979 Nov;44(6):1178–1182. doi: 10.1016/0002-9149(79)90185-1. [DOI] [PubMed] [Google Scholar]
  5. Dämmgen J., Kadatz R., Diederen W. Action of AR-L 115 BS on myocardial oxygen consumption, cardiac performance and vascular resistance and capacitance. Arzneimittelforschung. 1981;31(1A):151–154. [PubMed] [Google Scholar]
  6. Hauf G. F., Bubenheimer P., Roskamm H. The acute effect of a new positive inotropic agent (AR-L 115 BS) on cardiac hemodynamics and contractility in patients with severe chronic congestive heart failure. Arzneimittelforschung. 1981;31(1A):253–256. [PubMed] [Google Scholar]
  7. Hindman M. C., Slosky D. A., Peter R. H., Newman G. E., Jones R. H., Wallace A. G. Rest and exercise hemodynamic effects of oral hydralazine in patients with coronary artery disease and left ventricular dysfunction. Circulation. 1980 Apr;61(4):751–758. doi: 10.1161/01.cir.61.4.751. [DOI] [PubMed] [Google Scholar]
  8. Pouleur H., Rousseau M. F., van Mechelen H., Roncoroni L., Ries A., Charlier A. A. Cardiovascular effects of AR-L115 BS in conscious dogs with and without chronic congestive heart failure. J Cardiovasc Pharmacol. 1982 May-Jun;4(3):409–418. doi: 10.1097/00005344-198205000-00011. [DOI] [PubMed] [Google Scholar]
  9. Roth W., Beschke K., Jauch R., Zimmer A., Koss F. W. Fully automated high-performance liquid chromatography. A new chromatograph for pharmacokinetic drug monitoring by direct injection of body fluids. J Chromatogr. 1981 Jan 2;222(1):13–22. [PubMed] [Google Scholar]
  10. Solaro R. J., Rüegg J. C. Stimulation of Ca++ binding and ATPase activity of dog cardiac myofibrils by AR-L 115BS, a novel cardiotonic agent. Circ Res. 1982 Sep;51(3):290–294. doi: 10.1161/01.res.51.3.290. [DOI] [PubMed] [Google Scholar]
  11. Thormann J., Kramer W., Schlepper M. Hemodynamic and myocardial energetic changes induced by the new cardiotonic agent, AR-L 115, in patients with coronary artery disease. Am Heart J. 1982 Dec;104(6):1294–1302. doi: 10.1016/0002-8703(82)90159-4. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES